COVID-19 hit MSMEs can tap new relief window from January 1 Premium
The Hindu
Relief for MSMEs embroiled in disputes with govt. agencies due to COVID-19: Centre revives Vivad Se Vishwas I scheme till March 31.
The new year could ring in some relief for India’s Micro, Small and Medium Enterprises (MSMEs) embroiled in disputes with central government agencies due to the COVID-19 pandemic, with the Centre reviving a scheme to settle their claims in such cases.
Starting January 1, 2024, MSMEs can submit fresh claims under the Vivad Se Vishwas I scheme, which had originally admitted claims between mid-April to end of July this year. The new window for firms to file claims under the scheme, which had settled ₹650 crore in almost 44,000 cases by the beginning of December, will now be kept open till March 31.
Also Read | Centre grants about ₹250 crore to settle MSME disputes as pandemic relief
“It has been brought to the notice of this Department that eligible MSMEs could not lodge their claims on the portals because of lack of information about the scheme,” the Department of Expenditure in the Finance Ministry said in an office memo dated December 22. “In view of above, it has been decided that eligible claims under the subject scheme can now also be submitted from 1.1.2024 to 31.03.2024,” the memo added.
Announced by Finance Minister Nirmala Sitharaman in the Union Budget 2023-24, the Vivad Se Vishwas (VSVS) I scheme was aimed at providing relief to MSMEs unable to comply with central government contracts due to the pandemic. Launched on April 11, it covered all procurement contracts related to goods, services and works entered into by government departments.
Also Read | Centre settles more than 43000 MSME claims; refunds ₹700 cr.
Rupee hits all-time low at 85.20 against USD due to strong greenback, rising crude oil prices, and weak domestic markets.
Viatris faces U.S. FDA import alert for products from Indore plant, exceptions made for certain shortages.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.